Drug Database
MO

morphine (Intramorph / Duramorph / Epimorph)

✓ Approved

Pfizer, Inc. · OPRD1 · Small Molecule

What is morphine?

morphine is a small molecule developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intraspinal/intrathecal injection.

Drug Profile

Brand NamesIntramorph, Duramorph, Epimorph
CompanyPfizer, Inc.
Drug ClassSmall Molecule
Molecular TargetOPRD1, OPRK1, OPRM1
RouteInjectable (Others), Intraspinal/Intrathecal Injection
StatusApproved

Mechanism of Action

Molecular Targets

morphine acts on 3 molecular targets:

OPRD1opioid receptor delta 1 (DOR, OPRD)
OPRK1opioid receptor kappa 1 (KOR1, OPRK)
OPRM1opioid receptor mu 1 (MOR1, LMOR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

morphine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved

Related Research Articles

PubMedCureus2026-08-30

Analgesic Efficacy and Safety of Intrathecal Morphine in Surgical Patients: A Narrative Review.

Veilleux Chloe P CP, Omsberg Alison R AR, Richard Janelle M JM, Quaye Aurora N AN

It is well established that intrathecal morphine (ITM) provides prolonged postoperative analgesia and reduces systemic opioid requirements across a wide range of surgical procedures. Although extensive evidence supports the efficacy and safety of ITM, concern for delayed respiratory depression persists. Additionally, there is no standard approach for ITM dosing or postprocedural monitoring practices across institutions or medical societies, leading to wide variability that further contributes to inconsistent adoption. In this narrative review, we synthesize contemporary evidence on the pharmacology, analgesic efficacy, and risk profile of ITM and evaluate how current evidence aligns with existing postprocedural monitoring recommendations. A structured literature review identified clinical trials, observational studies, systematic reviews, and practice guidelines published within the past 20 years that evaluated perioperative ITM use. Across surgical populations, ITM is associated with reductions in postoperative pain scores and systemic opioid consumption at contemporary doses. At these doses, the incidence of respiratory depression was low and comparable to that observed with intravenous opioids. Reported respiratory events were strongly associated with patient-specific risk factors. Overall, current evidence supports the use of ITM as an effective analgesic modality with an acceptable safety profile. These findings support a risk-stratified approach to postprocedural monitoring that accounts for patient comorbidities and the ITM dose administered.

PubMedPain research & management2026-08-30

Nursing-Integrated Photobiomodulation Therapy for Post-Sternotomy Pain Management: A Retrospective Analysis of Acute Pain Alleviation and Opioid Sparing in a Single-Center Cohort.

Wang Yan Y, Yu Yun Y, Kang Yubei Y, Jin Hua H et al.

Postoperative pain is common among cardiac surgery patients, with some experiencing moderate to severe pain that persists for months. Photobiomodulation (PBM)-red light therapy, as a physical therapy, has been validated for promoting wound healing and alleviating neuropathic pain. This study aims to investigate the efficacy and safety of red light therapy in relieving acute postoperative pain in patients undergoing median sternotomy for cardiac surgery. This single-center retrospective cohort study included 264 patients who underwent cardiac surgery at Nanjing Drum Tower Hospital between January 2024 and February 2025. Among them, 184 patients were used as the control group, and the patients in the control group did not receive red light therapy during their stay in the CICU, while 80 patients in the observation group received PBM within 2 h after entering the CICU on the day of surgery. The incidence of acute postoperative pain, critical-care pain observation tool (CPOT) scores, morphine milligram equivalents per kilogram (MME/kg), and wound healing outcomes were compared between the two groups. The incidence of acute pain was significantly lower in the observation group than in the control group (38.8% vs 57.1%, p < 0.05). Additionally, CPOT scores and MME/kg were significantly reduced in the observation group (p < 0.05). No significant differences were observed in postoperative drainage output or the incidence of poor wound healing between the two groups (p > 0.05). In this retrospective cohort, early application of red light therapy was associated with alleviated acute postoperative pain and reduced opioid consumption, with no observed increase in wound-related complications. These findings suggest that PBM may serve as a safe and effective nonpharmacological adjunct for postoperative pain management in cardiac surgery patients.

PubMedCureus2026-08-29

Preoperative Gabapentin in Pediatric Anterior Cruciate Ligament Reconstruction With Peripheral Nerve Blockade: A Retrospective Cohort Study.

Halpern Lloyd M LM, Corell Charlotte C, Perrins K K, Zhang De-An DA et al.

Background Preoperative gabapentin has been shown to reduce postoperative pain and opioid consumption following anterior cruciate ligament reconstruction (ACLR) in adult patients treated with local infiltration analgesia. Its effectiveness in pediatric patients receiving peripheral nerve blockade for ACLR remains unclear. Methods We conducted a retrospective, single-center cohort study of pediatric patients (<18 years) undergoing ACLR from 2019 to 2024. All patients received anterior sciatic and adductor canal peripheral nerve blocks. Patients were stratified by receipt of preoperative gabapentin. The primary outcome was total postoperative opioid usage prior to hospital discharge (morphine milligram equivalents, MME). Secondary outcomes included pain scores, sedation, block efficacy, and length of stay. Multivariable linear regression was performed adjusting for patient demographics, intraoperative opioid usage, anesthesiologist, and tourniquet time. Results A total of 79 patients were enrolled in the study, with 55 in the Gabapentin group and 24 in the No Gabapentin group. Postoperative opioid consumption was low and not significantly different between groups (Gabapentin 4.1 ± 9.2 vs No Gabapentin 5.2 ± 5.7 MME, p=0.08). In adjusted analysis, preoperative gabapentin was not associated with postoperative opioid use (β = -0.56, p=0.25). Pain scores, sedation, block efficacy, and length of stay were similar between groups. Intraoperative opioid use was significantly higher in the Gabapentin group (p<0.001). Nearly one-third of patients required no postoperative opioids prior to discharge. Conclusions Preoperative gabapentin was not associated with a detectable reduction in postoperative opioid use or improvement in pain control in pediatric ACLR patients receiving adductor canal and anterior sciatic peripheral nerve blocks. When highly effective regional anesthesia is employed, gabapentin may provide limited incremental benefit.

PubMedFrontiers in psychiatry2026-08-28

Morphine and nicotine intake in high drinking in the dark mice is reduced by informatics-nominated and translationally relevant compounds.

Ginder Darren E DE, Palacios Jonathan J, Stewart Madeleine M, Jensen Bryan E BE et al.

Recent studies have identified an important role for neuroinflammatory signaling in alcohol and substance use. Dysregulation of neuroimmune signaling has been shown to be involved in the risk for drinking to intoxication, and pharmacologically targeting immune pathways can reduce early-stage and chronic binge-like alcohol drinking. High drinking in the dark (HDID) mice also consume other drugs of abuse, such as morphine and nicotine. Thus, this study aimed to explore anti-inflammatory compounds to reduce morphine and nicotine intake in a genetic mouse model for substance use disorder. We tested whether male and female inbred HDID mice will consume pharmacologically relevant levels of morphine and nicotine using the limited-access drinking in the dark assay (n = 7-12/sex/line). Drug intake was correlated with blood levels of morphine and nicotine metabolites (morphine-3-glucuronide and cotinine, respectively). We next tested whether the anti-inflammatory compounds terreic acid, pergolide, and apremilast would reduce morphine or nicotine intake (n = 11-14/sex/line/drug). Both inbred HDID (iHDID)-1 and iHDID-2 mouse lines drank pharmacologically relevant amounts of morphine and nicotine, where we observed a significant positive correlation between morphine and morphine-3-glucuronide in iHDID-2 male mice (p = 0.04) and a significant positive correlation between nicotine and cotinine in iHDID-2 female mice (p = 0.006). Terreic acid, pergolide, and apremilast significantly reduced morphine and nicotine intake in both lines and sexes. These findings highlight the versatility of iHDID-1 and iHDID-2 mice for both the consumption of drugs of abuse and as a model to test potential therapeutics to reduce drug intake. The results here provide further evidence that targeting inflammatory signaling offers promise for reducing opioid and nicotine use.

PubMedThe European respiratory journal2026-08-28

ERJ Podcast August 2026: Fentanyl or morphine for persistent dyspnoea in COPD.

PubMedInternational journal of obstetric anesthesia2026-08-28

Implementation of a multimodal analgesic protocol after vaginal delivery and postpartum opioid consumption: a single-center retrospective study (2018-2023).

Chau Tyler B TB, Veire Austin M AM, Dang Simon S, Hall Alexander G AG et al.

We investigated the effect of a standardized protocol with a multimodal order set on in-hospital opioid consumption and discharge prescription, emphasizing non-opioid medications over rescue oxycodone. This single-center retrospective study examined vaginal delivery patients in 2018 (pre-protocol) and 2023 (post-protocol). Outcomes included inpatient opioid use, milligram morphine equivalents, and outpatient opioid prescriptions. Multivariable regression analyzed associations with clinical and demographic covariates. Unadjusted inpatient opioid administration decreased from 40.85% (2018, n = 2666) to 5.87% (2023, n = 2316) (P < 0.001), and among those administered opioids, there was an average decrease of 11.2 mg morphine equivalents (P < 0.001). Adjusted models showed that White patients, while inpatient, were 25% less likely to receive an opioid and given 2.98 mg morphine equivalents less compared with Black patients (P < 0.001). Outpatient prescription rates declined from unadjusted 19.2% to 1.9% (P < 0.001). Implementation of a multimodal analgesia regimen was associated with significant reductions in opioid exposure after vaginal delivery.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about morphine